CEO Mike Mahoney said during the company's morning earnings call that Boston Scientific has "elected to temporarily pause" a trial of its Farapulse device in patients with atrial fibrillation who ...

Boston Scientific (NYSE:BSX) faced a 4.3% dip in its stock price following the news of a temporary pause in the trial for its FARAPULSE Pulse Field Ablation system. The pause comes as the company ...